Phibro Animal Health (PAHC) Cash from Financing Activities (2013 - 2026)

Phibro Animal Health has reported Cash from Financing Activities for 14 years, with the latest figure at -$1.6 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 79.2% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$6.6 million, a 103.17% decrease from a year earlier, with the FY2026 full-year figure at -$6.6 million, down 103.17% from the prior year.
• Cash from Financing Activities was -$1.6 million for Q2 2026 at Phibro Animal Health, up from -$2.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $276.3 million in Q4 2024, with the low at -$32.2 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is $13.5 million, with a median of $790000.0 recorded in 2023.
• The largest YoY upside for Cash from Financing Activities was 1979.09% in 2024 against a maximum downside of 2352.85% in 2024.
• Over 5 years, Cash from Financing Activities stood at $3.7 million in 2022, then sank by 495.72% to -$14.7 million in 2023, then soared by 1979.09% to $276.3 million in 2024, then tumbled by 106.87% to -$19.0 million in 2025, then soared by 91.49% to -$1.6 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.6 million (Q2 2026), -$2.3 million (Q1 2026), and -$19.0 million (Q4 2025), per Business Quant data.